The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

AstraZeneca (LSE:AZN) received US FDA approval for IMFINZI (durvalumab) with BCG therapy in BCG naïve, high risk non muscle invasive bladder cancer, based on positive Phase III data showing a ...

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of ...

The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

Eli Lilly announced plans to acquire three early and mid-stage vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — for a combined $3.8 billion. Blackstone Life Sciences is ...

May 27 (Reuters) - AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline for ...

An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...